Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Oster G, et al. Among authors: traylor l. Postgrad Med. 2016 Nov;128(8):731-739. doi: 10.1080/00325481.2016.1241663. Epub 2016 Oct 24. Postgrad Med. 2016. PMID: 27690710 Clinical Trial.
A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.
DeVries JH, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM. DeVries JH, et al. Among authors: traylor l. Eur Endocrinol. 2014 Feb;10(1):23-30. doi: 10.17925/EE.2014.10.01.23. Epub 2014 Feb 28. Eur Endocrinol. 2014. PMID: 29872460 Free PMC article.
Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
Owens DR, Traylor L, Dain MP, Landgraf W. Owens DR, et al. Among authors: traylor l. Diabetes Res Clin Pract. 2014 Nov;106(2):264-74. doi: 10.1016/j.diabres.2014.08.003. Epub 2014 Aug 12. Diabetes Res Clin Pract. 2014. PMID: 25195151 Free article.
Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
Polonsky W, Traylor L, Gao L, Wei W, Ameer B, Stuhr A, Vlajnic A. Polonsky W, et al. Among authors: traylor l. J Diabetes Complications. 2017 Mar;31(3):562-568. doi: 10.1016/j.jdiacomp.2016.11.018. Epub 2016 Dec 8. J Diabetes Complications. 2017. PMID: 28040350
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A. Owens DR, et al. Among authors: traylor l. Diabetes Obes Metab. 2017 Nov;19(11):1546-1554. doi: 10.1111/dom.12966. Epub 2017 Jul 27. Diabetes Obes Metab. 2017. PMID: 28449412
31 results